Cervical cancer screening programme 2023

Suomeksi

Screening programme overview

– The national cervical cancer screening programme has been running since the 1970s. In 2023 the screening method was either HPV-testing (82%) or Pap testing (18%) depending on the municipality.

– The target population, i.e., ages 30 to 65, were invited for routine screening at ages divisible by five. In some municipalities those aged 25 were also invited. In addition, those who had previously been detected with a mild positive screening result (HPV-positivity, ASC-US, LSIL) and were not referred to further examinations, received an invitation for risk group screening.

– The size of the statuory routine screening target population (ages 30-65) was 277 191 persons and of these 277 159 (99,99%) person’s contacts were delivered to the screening providers for sending the invitations.

– Out of the target population in 2023, 73% attended screening. In routine screening 5,5% were recommended risk group screening and 1,2% were referred for further examinations. In risk group screening 2,3% received a recommendation to another risk group screen and 41,5% were referred to further examinations.

– The method of the further examination was colposcopy, where altogether 39 cervical cancers and 1 408 severe precancers were detected.

Whole country

Screening process

2023

Routine screening age	Invited	Participated (of invited)		Borderline (of those who participated)		Referral (of those who participated)		Had a colposcopy (of those referred)		Histological HSIL+ (of those who had colposcopy)
	N	N	%	N	%	N	%	N	%	N	%
25	13760	8000	58.1	1025	12.8	49	0.6	42	85.7	21	50.0
30	35044	22996	65.6	2259	9.8	583	2.5	485	83.2	203	41.9
35	35680	24623	69.0	1684	6.8	433	1.8	372	85.9	176	47.3
40	36498	26518	72.7	1461	5.5	380	1.4	337	88.7	156	46.3
45	33889	25370	74.9	1308	5.2	297	1.2	237	79.8	85	35.9
50	29040	22362	77.0	1115	5.0	222	1.0	183	82.4	63	34.4
55	35087	26600	75.8	1191	4.5	200	0.8	158	79.0	38	24.1
60	37135	28044	75.5	1097	3.9	191	0.7	158	82.7	42	26.6
65	34786	26050	74.9	932	3.6	137	0.5	118	86.1	34	28.8
Total	290919	210563	72.4	12072	5.7	2492	1.2	2090	83.9	818	39.1

2022

Routine screening age	Invited	Participated (of invited)		Borderline (of those who participated)		Referral (of those who participated)		Had a colposcopy (of those referred)		Histological HSIL+ (of those who had colposcopy)
	N	N	%	N	%	N	%	N	%	N	%
25	14331	8069	56.3	981	12.2	82	1.0	83	101.2	53	63.9
30	35644	22644	63.5	2278	10.1	461	2.0	442	95.9	223	50.5
35	33299	22470	67.5	1518	6.8	365	1.6	356	97.5	187	52.5
40	35593	25594	71.9	1499	5.9	350	1.4	340	97.1	167	49.1
45	34143	25307	74.1	1261	5.0	291	1.1	281	96.6	128	45.6
50	29980	22713	75.8	1161	5.1	198	0.9	188	94.9	57	30.3
55	35913	27127	75.5	1200	4.4	172	0.6	168	97.7	44	26.2
60	36763	27644	75.2	1093	4.0	139	0.5	134	96.4	31	23.1
65	36325	27139	74.7	889	3.3	113	0.4	109	96.5	28	25.7
Total	291991	208707	71.5	11880	5.7	2171	1.0	2101	96.8	918	43.7

2021

Routine screening age	Invited	Participated (of invited)		Borderline (of those who participated)		Referral (of those who participated)		Had a colposcopy (of those referred)		Histological HSIL+ (of those who had colposcopy)
	N	N	%	N	%	N	%	N	%	N	%
25	14470	8374	57.9	926	11.1	108	1.3	103	95.4	50	48.5
30	34991	22861	65.3	2455	10.7	538	2.4	500	92.9	254	50.8
35	33472	22957	68.6	1613	7.0	389	1.7	352	90.5	205	58.2
40	34296	25052	73.0	1421	5.7	304	1.2	281	92.4	149	53.0
45	34032	25457	74.8	1303	5.1	269	1.1	245	91.1	118	48.2
50	31227	23880	76.5	1207	5.1	196	0.8	183	93.4	60	32.8
55	36213	27441	75.8	1230	4.5	182	0.7	160	87.9	63	39.4
60	36771	27898	75.9	1035	3.7	118	0.4	101	85.6	38	37.6
65	15849	11659	73.6	441	3.8	41	0.4	38	92.7	11	28.9
Total	271321	195579	72.1	11631	5.9	2145	1.1	1963	91.5	948	48.3

2020

Routine screening age	Invited	Participated (of invited)		Borderline (of those who participated)		Referral (of those who participated)		Had a colposcopy (of those referred)		Histological HSIL+ (of those who had colposcopy)
	N	N	%	N	%	N	%	N	%	N	%
25	14783	8241	55.7	699	8.5	65	0.8	64	98.5	35	54.7
30	35161	22232	63.2	2297	10.3	371	1.7	362	97.6	202	55.8
35	34321	22726	66.2	1489	6.6	314	1.4	311	99.0	171	55.0
40	33762	23811	70.5	1244	5.2	267	1.1	265	99.3	143	54.0
45	33192	23971	72.2	1141	4.8	200	0.8	199	99.5	95	47.7
50	32238	23988	74.4	1093	4.6	167	0.7	168	100.6	57	33.9
55	36432	26953	74.0	1119	4.2	146	0.5	147	100.7	57	38.8
60	36844	27361	74.3	983	3.6	125	0.5	125	100.0	48	38.4
65	15729	11277	71.7	397	3.5	33	0.3	33	100.0	6	18.2
Total	272462	190560	69.9	10462	5.5	1688	0.9	1674	99.2	814	48.6

2019

Routine screening age	Invited	Participated (of invited)		Borderline (of those who participated)		Referral (of those who participated)		Had a colposcopy (of those referred)		Histological HSIL+ (of those who had colposcopy)
	N	N	%	N	%	N	%	N	%	N	%
25	14574	7788	53.4	580	7.4	63	0.8	64	101.6	36	56.2
30	33997	21541	63.4	2130	9.9	400	1.9	398	99.5	227	57.0
35	34971	23582	67.4	1634	6.9	316	1.3	317	100.3	173	54.6
40	33472	24150	72.1	1290	5.3	248	1.0	248	100.0	129	52.0
45	31906	23478	73.6	1152	4.9	221	0.9	220	99.5	92	41.8
50	32631	24690	75.7	1179	4.8	191	0.8	191	100.0	72	37.7
55	37073	28133	75.9	1130	4.0	140	0.5	140	100.0	42	30.0
60	36563	28022	76.6	1078	3.8	140	0.5	140	100.0	53	37.9
65	13639	10374	76.1	399	3.8	34	0.3	34	100.0	11	32.4
Total	268826	191758	71.3	10572	5.5	1753	0.9	1752	99.9	835	47.7

Participation rate

2023

Target group	Target population	Invited (of target population)		Participated (of invited)
	N	N	%	N	%
Routine screening (30-65)	277191	277159	100.0	202563	73.1
Routine screening (25-65)	307104	290919	94.7	210563	72.4
Follow-up screening (25-69)	–	10544	–	8695	82.5
Total	–	301463	–	219258	72.7

Routine screening age	Target population	Invited (of target population)		Participated (of invited)
	N	N	%	N	%
25	29913	13760	46.0	8000	58.1
30	35026	35044	100.1	22996	65.6
35	35627	35680	100.1	24623	69.0
40	36510	36498	100.0	26518	72.7
45	33901	33889	100.0	25370	74.9
50	29053	29040	100.0	22362	77.0
55	35127	35087	99.9	26600	75.8
60	37145	37135	100.0	28044	75.5
65	34802	34786	100.0	26050	74.9
Total	307104	290919	94.7	210563	72.4

2022

Target group	Target population	Invited (of target population)		Participated (of invited)
	N	N	%	N	%
Routine screening (30-65)	277795	277660	100.0	200638	72.3
Routine screening (25-65)	308716	291991	94.6	208707	71.5
Follow-up screening (25-69)	–	12719	–	10195	80.2
Total	–	304710	–	218902	71.8

Routine screening age	Target population	Invited (of target population)		Participated (of invited)
	N	N	%	N	%
25	30921	14331	46.3	8069	56.3
30	35640	35644	100.0	22644	63.5
35	33275	33299	100.1	22470	67.5
40	35631	35593	99.9	25594	71.9
45	34192	34143	99.9	25307	74.1
50	30031	29980	99.8	22713	75.8
55	35953	35913	99.9	27127	75.5
60	36750	36763	100.0	27644	75.2
65	36323	36325	100.0	27139	74.7
Total	308716	291991	94.6	208707	71.5

2021

Target group	Target population	Invited (of target population)		Participated (of invited)
	N	N	%	N	%
Routine screening (30-60)	241230	241002	99.9	175546	72.8
Routine screening (25-65)	309902	271321	87.6	195579	72.1
Follow-up screening (25-69)	–	12122	–	10001	82.5
Total	–	283443	–	205580	72.5

Routine screening age	Target population	Invited (of target population)		Participated (of invited)
	N	N	%	N	%
25	31292	14470	46.2	8374	57.9
30	34998	34991	100.0	22861	65.3
35	33508	33472	99.9	22957	68.6
40	34371	34296	99.8	25052	73.0
45	34110	34032	99.8	25457	74.8
50	31242	31227	100.0	23880	76.5
55	36211	36213	100.0	27441	75.8
60	36790	36771	99.9	27898	75.9
65	37380	15849	42.4	11659	73.6
Total	309902	271321	87.6	195579	72.1

2020

Target group	Target population	Invited (of target population)		Participated (of invited)
	N	N	%	N	%
Routine screening (30-60)	242081	241950	99.9	171042	70.7
Routine screening (25-65)	311832	272462	87.4	190560	69.9
Follow-up screening (25-69)	–	3955	–	2640	66.8
Total	–	276417	–	193200	69.9

Routine screening age	Target population	Invited (of target population)		Participated (of invited)
	N	N	%	N	%
25	32519	14783	45.5	8241	55.7
30	35249	35161	99.8	22232	63.2
35	34309	34321	100.0	22726	66.2
40	33819	33762	99.8	23811	70.5
45	33236	33192	99.9	23971	72.2
50	32225	32238	100.0	23988	74.4
55	36431	36432	100.0	26953	74.0
60	36812	36844	100.1	27361	74.3
65	37232	15729	42.2	11277	71.7
Total	311832	272462	87.4	190560	69.9

2019

Target group	Target population	Invited (of target population)		Participated (of invited)
	N	N	%	N	%
Routine screening (30-60)	241524	240613	99.6	173596	72.1
Routine screening (25-65)	312990	268826	85.9	191758	71.3
Follow-up screening (25-69)	–	14572	–	9936	68.2
Total	–	283398	–	201694	71.2

Routine screening age	Target population	Invited (of target population)		Participated (of invited)
	N	N	%	N	%
25	33535	14574	43.5	7788	53.4
30	34313	33997	99.1	21541	63.4
35	35163	34971	99.5	23582	67.4
40	33600	33472	99.6	24150	72.1
45	31996	31906	99.7	23478	73.6
50	32707	32631	99.8	24690	75.7
55	37114	37073	99.9	28133	75.9
60	36631	36563	99.8	28022	76.6
65	37931	13639	36.0	10374	76.1
Total	312990	268826	85.9	191758	71.3

Screening results

Proportion of attended

2023

Target group	Participated	Referral		Borderline		Normal		Inadequate/ missing		HPV-tested		HPV-positive (of those HPV-tested)
	N	N	%	N	%	N	%	N	%	N	%	N	%
Routine screening (30-65)	202563	2443	1.2	11047	5.5	188994	93.3	79	0.0	166143	82.0	11503	5.7
Routine screening (25-65)	210563	2492	1.2	12072	5.7	195903	93.0	96	0.0	166145	78.9	11504	5.5
Follow-up screening (25-69)	8695	3607	41.5	196	2.3	4876	56.1	16	0.2	7291	83.9	3446	39.6
Total	219258	6099	2.8	12268	5.6	200779	91.6	112	0.1	173436	79.1	14950	6.8

Routine screening age	Participated	Referral		Borderline		Normal		Inadequate/ missing		HPV-tested		HPV-positive (of those HPV-tested)
	N	N	%	N	%	N	%	N	%	N	%	N	%
25	8000	49	0.6	1025	12.8	6909	86.4	17	0.2	2	0.0	1	0.0
30	22996	583	2.5	2259	9.8	20141	87.6	13	0.1	17859	77.7	2536	11.0
35	24623	433	1.8	1684	6.8	22495	91.4	11	0.0	20663	83.9	1891	7.7
40	26518	380	1.4	1461	5.5	24667	93.0	10	0.0	22042	83.1	1553	5.9
45	25370	297	1.2	1308	5.2	23756	93.6	9	0.0	21090	83.1	1302	5.1
50	22362	222	1.0	1115	5.0	21018	94.0	7	0.0	18639	83.4	1053	4.7
55	26600	200	0.8	1191	4.5	25204	94.8	5	0.0	22022	82.8	1170	4.4
60	28044	191	0.7	1097	3.9	26745	95.4	11	0.0	22814	81.4	1089	3.9
65	26050	137	0.5	932	3.6	24968	95.8	13	0.0	21014	80.7	909	3.5
Total	210563	2492	1.2	12072	5.7	195903	93.0	96	0.0	166145	78.9	11504	5.5

2022

Target group	Participated	Referral		Borderline		Normal		Inadequate/ missing		HPV-tested		HPV-positive (of those HPV-tested)
	N	N	%	N	%	N	%	N	%	N	%	N	%
Routine screening (30-65)	200638	2089	1.0	10899	5.4	187509	93.5	141	0.1	155456	77.5	10667	5.3
Routine screening (25-65)	208707	2171	1.0	11880	5.7	194514	93.2	142	0.1	155465	74.5	10668	5.1
Follow-up screening (25-69)	10195	3657	35.9	266	2.6	6264	61.4	8	0.1	8537	83.7	3514	34.5
Total	218902	5828	2.7	12146	5.5	200778	91.7	150	0.1	164002	74.9	14182	6.5

Routine screening age	Participated	Referral		Borderline		Normal		Inadequate/ missing		HPV-tested		HPV-positive (of those HPV-tested)
	N	N	%	N	%	N	%	N	%	N	%	N	%
25	8069	82	1.0	981	12.2	7005	86.8	1	0.0	9	0.1	1	0.0
30	22644	461	2.0	2278	10.1	19891	87.8	14	0.1	18334	81.0	2514	11.1
35	22470	365	1.6	1518	6.8	20577	91.6	10	0.0	17792	79.2	1624	7.2
40	25594	350	1.4	1499	5.9	23727	92.7	18	0.1	19983	78.1	1495	5.8
45	25307	291	1.1	1261	5.0	23739	93.8	16	0.1	19712	77.9	1208	4.8
50	22713	198	0.9	1161	5.1	21345	94.0	9	0.0	17467	76.9	1013	4.5
55	27127	172	0.6	1200	4.4	25741	94.9	14	0.1	20827	76.8	1045	3.9
60	27644	139	0.5	1093	4.0	26386	95.4	26	0.1	21098	76.3	979	3.5
65	27139	113	0.4	889	3.3	26103	96.2	34	0.1	20243	74.6	789	2.9
Total	208707	2171	1.0	11880	5.7	194514	93.2	142	0.1	155465	74.5	10668	5.1

2021

Target group	Participated	Referral		Borderline		Normal		Inadequate/ missing		HPV-tested		HPV-positive (of those HPV-tested)
	N	N	%	N	%	N	%	N	%	N	%	N	%
Routine screening (30-60)	175546	1996	1.1	10264	5.8	163155	92.9	131	0.1	122445	69.8	9612	5.5
Routine screening (25-65)	195579	2145	1.1	11631	5.9	181663	92.9	140	0.1	132669	67.8	10059	5.1
Follow-up screening (25-69)	10001	3148	31.5	514	5.1	6332	63.3	7	0.1	8010	80.1	3202	32.0
Total	205580	5293	2.6	12145	5.9	187995	91.4	147	0.1	140679	68.4	13261	6.5

Routine screening age	Participated	Referral		Borderline		Normal		Inadequate/ missing		HPV-tested		HPV-positive (of those HPV-tested)
	N	N	%	N	%	N	%	N	%	N	%	N	%
25	8374	108	1.3	926	11.1	7335	87.6	5	0.1	13	0.2	2	0.0
30	22861	538	2.4	2455	10.7	19842	86.8	26	0.1	17092	74.8	2710	11.9
35	22957	389	1.7	1613	7.0	20932	91.2	23	0.1	16569	72.2	1663	7.2
40	25052	304	1.2	1421	5.7	23310	93.0	17	0.1	17716	70.7	1307	5.2
45	25457	269	1.1	1303	5.1	23873	93.8	12	0.0	17861	70.2	1136	4.5
50	23880	196	0.8	1207	5.1	22466	94.1	11	0.0	16333	68.4	970	4.1
55	27441	182	0.7	1230	4.5	26012	94.8	17	0.1	18676	68.1	995	3.6
60	27898	118	0.4	1035	3.7	26720	95.8	25	0.1	18198	65.2	831	3.0
65	11659	41	0.4	441	3.8	11173	95.8	4	0.0	10211	87.6	445	3.8
Total	195579	2145	1.1	11631	5.9	181663	92.9	140	0.1	132669	67.8	10059	5.1

2020

Target group	Participated	Referral		Borderline		Normal		Inadequate/ missing		HPV-tested		HPV-positive (of those HPV-tested)
	N	N	%	N	%	N	%	N	%	N	%	N	%
Routine screening (30-60)	171042	1590	0.9	9366	5.5	160076	93.6	10	0	109280	63.9	8667	5.1
Routine screening (25-65)	190560	1688	0.9	10462	5.5	178397	93.6	13	0	118090	62.0	9057	4.8
Follow-up screening (25-69)	2640	386	14.6	304	11.5	1950	73.9	0	0	1300	49.2	448	17.0
Total	193200	2074	1.1	10766	5.6	180347	93.3	13	0	119390	61.8	9505	4.9

Routine screening age	Participated	Referral		Borderline		Normal		Inadequate/ missing		HPV-tested		HPV-positive (of those HPV-tested)
	N	N	%	N	%	N	%	N	%	N	%	N	%
25	8241	65	0.8	699	8.5	7477	90.7	0	0	7	0.1	0	0.0
30	22232	371	1.7	2297	10.3	19559	88.0	5	0	15258	68.6	2385	10.7
35	22726	314	1.4	1489	6.6	20921	92.1	2	0	15234	67.0	1509	6.6
40	23811	267	1.1	1244	5.2	22300	93.7	0	0	15498	65.1	1162	4.9
45	23971	200	0.8	1141	4.8	22629	94.4	1	0	15460	64.5	966	4.0
50	23988	167	0.7	1093	4.6	22727	94.7	1	0	15074	62.8	897	3.7
55	26953	146	0.5	1119	4.2	25688	95.3	0	0	16550	61.4	924	3.4
60	27361	125	0.5	983	3.6	26252	95.9	1	0	16206	59.2	824	3.0
65	11277	33	0.3	397	3.5	10844	96.2	3	0	8803	78.1	390	3.5
Total	190560	1688	0.9	10462	5.5	178397	93.6	13	0	118090	62.0	9057	4.8

2019

Target group	Participated	Referral		Borderline		Normal		Inadequate/ missing		HPV-tested		HPV-positive (of those HPV-tested)
	N	N	%	N	%	N	%	N	%	N	%	N	%
Routine screening (30-60)	173596	1656	1.0	9593	5.5	162344	93.5	3	0	107619	62.0	8411	4.8
Routine screening (25-65)	191758	1753	0.9	10572	5.5	179429	93.6	4	0	116931	61.0	8823	4.6
Follow-up screening (25-69)	9936	1098	11.1	725	7.3	8113	81.7	0	0	7498	75.5	1404	14.1
Total	201694	2851	1.4	11297	5.6	187542	93.0	4	0	124429	61.7	10227	5.1

Routine screening age	Participated	Referral		Borderline		Normal		Inadequate/ missing		HPV-tested		HPV-positive (of those HPV-tested)
	N	N	%	N	%	N	%	N	%	N	%	N	%
25	7788	63	0.8	580	7.4	7144	91.7	1	0	25	0.3	3	0.0
30	21541	400	1.9	2130	9.9	19009	88.2	2	0	13499	62.7	2114	9.8
35	23582	316	1.3	1634	6.9	21632	91.7	0	0	15456	65.5	1594	6.8
40	24150	248	1.0	1290	5.3	22612	93.6	0	0	15520	64.3	1162	4.8
45	23478	221	0.9	1152	4.9	22104	94.1	1	0	14911	63.5	925	3.9
50	24690	191	0.8	1179	4.8	23320	94.5	0	0	15219	61.6	925	3.7
55	28133	140	0.5	1130	4.0	26863	95.5	0	0	16871	60.0	840	3.0
60	28022	140	0.5	1078	3.8	26804	95.7	0	0	16143	57.6	851	3.0
65	10374	34	0.3	399	3.8	9941	95.8	0	0	9287	89.5	409	3.9
Total	191758	1753	0.9	10572	5.5	179429	93.6	4	0	116931	61.0	8823	4.6

Histological findings

Proportion of attended

2023

Target group	Participated	Cervical cancer		AIS		HSIL		LSIL		Normal/ benign		Other/ unknown		No further examinations
	N	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Routine screening (30-65)	202563	25	0.0	33	0.0	739	0.4	623	0.3	584	0.3	44	0.0	397	0.2
Routine screening (25-65)	210563	25	0.0	33	0.0	760	0.4	629	0.3	597	0.3	46	0.0	404	0.2
Follow-up screening (25-69)	8695	14	0.2	20	0.2	595	6.8	880	10.1	1380	15.9	146	1.7	574	6.6
Total	219258	39	0.0	53	0.0	1355	0.6	1509	0.7	1977	0.9	192	0.1	978	0.4

Routine screening age	Participated	Cervical cancer		AIS		HSIL		LSIL		Normal/ benign		Other/ unknown		No further examinations
	N	N	%	N	%	N	%	N	%	N	%	N	%	N	%
25	8000	0	0	0	0	21	0.3	6	0.1	13	0.2	2	0	7	0.1
30	22996	2	0	6	0	195	0.8	151	0.7	123	0.5	8	0	98	0.4
35	24623	9	0	7	0	160	0.6	107	0.4	87	0.4	2	0	61	0.2
40	26518	4	0	9	0	143	0.5	100	0.4	79	0.3	2	0	43	0.2
45	25370	3	0	8	0	74	0.3	76	0.3	75	0.3	1	0	60	0.2
50	22362	5	0	3	0	55	0.2	52	0.2	59	0.3	9	0	39	0.2
55	26600	1	0	0	0	37	0.1	57	0.2	56	0.2	7	0	42	0.2
60	28044	1	0	0	0	41	0.1	45	0.2	63	0.2	8	0	33	0.1
65	26050	0	0	0	0	34	0.1	35	0.1	42	0.2	7	0	21	0.1
Total	210563	25	0	33	0	760	0.4	629	0.3	597	0.3	46	0	404	0.2

2022

Target group	Participated	Cervical cancer		AIS		HSIL		LSIL		Normal/ benign		Other/ unknown		No further examinations
	N	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Routine screening (30-65)	200638	21	0.0	38	0.0	806	0.4	573	0.3	539	0.3	41	0.0	521	0.3
Routine screening (25-65)	208707	22	0.0	40	0.0	856	0.4	588	0.3	554	0.3	41	0.0	522	0.3
Follow-up screening (25-69)	10195	11	0.1	39	0.4	793	7.8	1028	10.1	1489	14.6	148	1.5	167	1.6
Total	218902	33	0.0	79	0.0	1649	0.8	1616	0.7	2043	0.9	189	0.1	689	0.3

Routine screening age	Participated	Cervical cancer		AIS		HSIL		LSIL		Normal/ benign		Other/ unknown		No further examinations
	N	N	%	N	%	N	%	N	%	N	%	N	%	N	%
25	8069	1	0	2	0	50	0.6	15	0.2	15	0.2	0	0	1	0.0
30	22644	2	0	10	0	211	0.9	113	0.5	101	0.4	5	0	47	0.2
35	22470	2	0	8	0	177	0.8	95	0.4	71	0.3	3	0	49	0.2
40	25594	10	0	8	0	149	0.6	88	0.3	84	0.3	1	0	45	0.2
45	25307	6	0	8	0	114	0.5	84	0.3	63	0.2	6	0	51	0.2
50	22713	0	0	3	0	54	0.2	59	0.3	65	0.3	7	0	58	0.3
55	27127	0	0	0	0	44	0.2	57	0.2	61	0.2	6	0	69	0.3
60	27644	0	0	0	0	31	0.1	40	0.1	55	0.2	8	0	94	0.3
65	27139	1	0	1	0	26	0.1	37	0.1	39	0.1	5	0	108	0.4
Total	208707	22	0	40	0	856	0.4	588	0.3	554	0.3	41	0	522	0.3

2021

Target group	Participated	Cervical cancer		AIS		HSIL		LSIL		Normal/ benign		Other/ unknown		No further examinations
	N	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Routine screening (30-60)	175546	38	0.0	28	0.0	821	0.5	479	0.3	411	0.2	45	0.0	174	0.1
Routine screening (25-65)	195579	38	0.0	29	0.0	881	0.5	514	0.3	455	0.2	46	0.0	183	0.1
Follow-up screening (25-69)	10001	13	0.1	30	0.3	666	6.7	891	8.9	1274	12.7	148	1.5	128	1.3
Total	205580	51	0.0	59	0.0	1547	0.8	1405	0.7	1729	0.8	194	0.1	311	0.2

Routine screening age	Participated	Cervical cancer		AIS		HSIL		LSIL		Normal/ benign		Other/ unknown		No further examinations
	N	N	%	N	%	N	%	N	%	N	%	N	%	N	%
25	8374	0	0.0	0	0	50	0.6	21	0.3	31	0.4	1	0.0	5	0.1
30	22861	5	0.0	7	0	242	1.1	135	0.6	97	0.4	14	0.1	38	0.2
35	22957	13	0.1	6	0	186	0.8	78	0.3	62	0.3	7	0.0	37	0.2
40	25052	6	0.0	5	0	138	0.6	61	0.2	64	0.3	7	0.0	23	0.1
45	25457	4	0.0	4	0	110	0.4	73	0.3	51	0.2	3	0.0	24	0.1
50	23880	6	0.0	1	0	53	0.2	65	0.3	50	0.2	8	0.0	13	0.1
55	27441	2	0.0	3	0	58	0.2	40	0.1	55	0.2	2	0.0	22	0.1
60	27898	2	0.0	2	0	34	0.1	27	0.1	32	0.1	4	0.0	17	0.1
65	11659	0	0.0	1	0	10	0.1	14	0.1	13	0.1	0	0.0	4	0.0
Total	195579	38	0.0	29	0	881	0.5	514	0.3	455	0.2	46	0.0	183	0.1

2020

Target group	Participated	Cervical cancer		AIS		HSIL		LSIL		Normal/ benign		Other/ unknown		No further examinations
	N	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Routine screening (30-60)	171042	27	0.0	36	0.0	710	0.4	343	0.2	332	0.2	129	0.1	16	0
Routine screening (25-65)	190560	27	0.0	36	0.0	751	0.4	366	0.2	360	0.2	134	0.1	17	0
Follow-up screening (25-69)	2640	2	0.1	3	0.1	105	4.0	91	3.4	119	4.5	65	2.5	1	0
Total	193200	29	0.0	39	0.0	856	0.4	457	0.2	479	0.2	199	0.1	18	0

Routine screening age	Participated	Cervical cancer		AIS		HSIL		LSIL		Normal/ benign		Other/ unknown		No further examinations
	N	N	%	N	%	N	%	N	%	N	%	N	%	N	%
25	8241	0	0	0	0	35	0.4	14	0.2	10	0.1	5	0.1	1	0
30	22232	3	0	6	0	193	0.9	69	0.3	71	0.3	20	0.1	9	0
35	22726	4	0	9	0	158	0.7	74	0.3	43	0.2	23	0.1	3	0
40	23811	7	0	10	0	126	0.5	55	0.2	47	0.2	20	0.1	2	0
45	23971	3	0	4	0	88	0.4	44	0.2	40	0.2	20	0.1	1	0
50	23988	2	0	5	0	50	0.2	40	0.2	53	0.2	18	0.1	0	0
55	26953	5	0	0	0	52	0.2	33	0.1	47	0.2	10	0.0	0	0
60	27361	3	0	2	0	43	0.2	28	0.1	31	0.1	18	0.1	1	0
65	11277	0	0	0	0	6	0.1	9	0.1	18	0.2	0	0.0	0	0
Total	190560	27	0	36	0	751	0.4	366	0.2	360	0.2	134	0.1	17	0